Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method
Year: 2024
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: We captured continuous glucose monitoring (CGM) metrics from a large online survey of adults with type 1 diabetes to determine how glycemic outcomes varied by insulin delivery form. RESEARCH DESIGN AND METHODS: Adults with type 1 diabetes from the T1D Exchange Registry/online communities completed the survey and contributed retrospective CGM data for up to 1 year. Self-reported glycemic outcomes and CGM measures were described overall and by insulin delivery method. RESULTS: The 926 participants completed the survey and provided CGM data. Mean ± SD age was 41.9 ± 15.7 years, and 50.8% reported using automated insulin delivery (AID). While AID users spent more time in range, 27.9% did not achieve time in range targets, 15.5% reported severe hypoglycemic events (SHEs), and 16.0% had CGM-detected level 2 hypoglycemic events. CONCLUSIONS: Despite use of diabetes technologies, many individuals are unable to achieve glycemic targets and experience severe hypoglycemia, highlighting the need for novel treatments.
Source: Diabetes Care
DOI: 10.2337/dc24-1474
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Eli Lilly and Company, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Bigfoot Biomedical, Insulet Corporation, MannKind Corporation, Dexcom, Tandem Diabetes Care, European Foundation for the Study of Diabetes, Novo Nordisk, National Institutes of Health, Abbott Diabetes Care, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences, Moonshot Research and Development Program
OpenAlex ID: W4405612426